Inspire Investing LLC Purchases 1,887 Shares of Xencor, Inc. (NASDAQ:XNCR)

Inspire Investing LLC boosted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 10.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,530 shares of the biopharmaceutical company’s stock after acquiring an additional 1,887 shares during the quarter. Inspire Investing LLC’s holdings in Xencor were worth $413,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Primecap Management Co. CA increased its holdings in shares of Xencor by 0.3% during the 2nd quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock valued at $172,570,000 after acquiring an additional 25,495 shares during the last quarter. Vanguard Group Inc. grew its holdings in Xencor by 3.6% during the first quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock valued at $155,154,000 after purchasing an additional 243,793 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Xencor by 9.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after purchasing an additional 335,881 shares during the period. Logos Global Management LP lifted its stake in shares of Xencor by 130.8% in the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after buying an additional 850,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Xencor by 6.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock worth $27,628,000 after buying an additional 87,979 shares during the period.

Xencor Stock Performance

Shares of NASDAQ XNCR opened at $21.36 on Friday. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -9.75 and a beta of 0.67. Xencor, Inc. has a one year low of $15.31 and a one year high of $26.84. The business has a fifty day simple moving average of $18.88 and a 200 day simple moving average of $20.12. The company has a current ratio of 6.92, a quick ratio of 6.92 and a debt-to-equity ratio of 0.02.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The business had revenue of $16.96 million during the quarter, compared to analyst estimates of $21.13 million. During the same quarter in the prior year, the company posted ($0.37) EPS. The company’s quarterly revenue was down 62.7% compared to the same quarter last year. Sell-side analysts expect that Xencor, Inc. will post -4.13 EPS for the current year.

Wall Street Analyst Weigh In

XNCR has been the topic of several recent analyst reports. Royal Bank of Canada lifted their target price on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. BMO Capital Markets reissued an “outperform” rating and set a $32.00 price objective on shares of Xencor in a research report on Tuesday, August 6th. Wedbush reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Xencor in a report on Monday, September 9th. Finally, JPMorgan Chase & Co. cut their price target on Xencor from $30.00 to $27.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.78.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.